Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.
Over the past few decades, great strides have been made to advance the field of allogeneic hematopoietic stem cell transplantation. The donor immune mediated graft-vs-tumor effect that follows the procedure is now widely accepted as the most effective form cancer immunotherapy available for patients with a variety of advanced hematological malignancies. Recognition that a transplanted immune system could cure patients with treatment refractory leukemia led to the development of ;low-intensity' conditioning regimens, which have improved the safety of the procedure and broadened the application of allogeneic immunotherapy to a growing list of neoplastic diseases. Here we discuss the investigational use of allogeneic transplantation as immunotherapy for patients with metastatic, treatment-refractory solid tumors.
Carvallo
Cristian
C
Urologic Oncology Branch, National Cancer Institute, Hematology Branch, National Heart Lung and Blood Institute, National Institutes for Health, Bethesda, MD, U.S.A.
Childs
Richard
R